Session » Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1489

“Continuous Reduction” in Serum RF Titers Predicts Low Disease Activity and Good Therapeutic Response in RA Patients Treated with TNF Inhibitors, but Does Not Relate to Clinical Outcomes during ABT Treatment

9:00AM-11:00AM: Abstract Number: 1465

Absolute Number of Regulatory T Cells Decreased While Osteopontin Increased in Peripheral Blood of New Onset Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1466

Altered Count of NK Cells and Non-Classical Monocyte Subpopulation in the Pre-Clinical Phase of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1481

Are ACPA Associated with More Bone Loss over Time in Patients with RA?

9:00AM-11:00AM: Abstract Number: 1501

Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate

9:00AM-11:00AM: Abstract Number: 1457

Association between Disease Activity and Radiographic Progression in the Current Treat-to-Target Paradigm of Rheumatoid Arthritis: Real World Data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry

9:00AM-11:00AM: Abstract Number: 1495

Baseline Characteristics of Methotrexate Inadequate Responder Patients with RA Who Achieved Low Disease Activity with Tofacitinib Monotherapy

9:00AM-11:00AM: Abstract Number: 1459

Bone Erosion Volume Changes Measured By HR-pQCT at 3-Months after Initiation of Anti-TNF Treatment Predicted Erosion Volume Changes at 1-Year in RA

9:00AM-11:00AM: Abstract Number: 1474

Circulating Transfer RNA-Derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1448

Clinical Impact of Articular Ultrasound in Diagnosis and Follow-up of Patients with Polyarthritis

9:00AM-11:00AM: Abstract Number: 1493

Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1450

Clinical Radiology Reports Are Unreliable for Assessment of Radiographic Structural Progression in US Veterans with Rheumatoid Arthritis Initiating Tumor Necrosis Factor Inhibitor Therapy

9:00AM-11:00AM: Abstract Number: 1452

Combination of Ultrasound Power Doppler-Verified Synovitis and Seropositivity Accurately Identifies Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1483

Comparison of Clinical Features of Seronegative and Seropositive Early Rheumatoid Arthritis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients

9:00AM-11:00AM: Abstract Number: 1453

Correlation between Clinical and Ultrasonographic Remission? the Effect of Non-Inflammatory Patient-Based Factors on Different Remission Definitions

9:00AM-11:00AM: Abstract Number: 1487

Correlation between Cytokine Levels and Power-Doppler Ultrasound Activity Is BMI Dependent, and Different in ACPA Positive and ACPA Negative RA with Wrist Arthritis

9:00AM-11:00AM: Abstract Number: 1447

Decreased Lymphatic Drainage in the Hands of Flaring RA Patients As Measured By Indocyanine Green Clearance Via Real Time Near Infrared Imaging

9:00AM-11:00AM: Abstract Number: 1455

Development of a Predictive Model of Radiological Damage in Patients with Rheumatoid Arthritis Based on Artificial Intelligence

9:00AM-11:00AM: Abstract Number: 1441

Diagnostic Performances of Antibodies Against Carbamylated Proteins in US Based Populations with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1442

Differential Chemical Isotope Labeling Liquid Chromatography Mass Spectrometry and a Universal Metabolome Standard Reveals a Metabolome Profile with Consistent Accuracy for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1463

Do Anti-Citrullinated Protein Antibodies and Anti-Sjögren’s-Syndrome-Related Antigen a Double Positive Patients with Secondary Sjögren’s Syndrome and RA Have Higher Joint Disease Activity?

9:00AM-11:00AM: Abstract Number: 1471

ECV304 Cells Self-Citrullinate Proteins Targeted By Anti-Citrullinated Protein/Peptide Autoantibodies from Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1490

Effects of Biologic Drugs on Prognosis of Rheumatoid Arthritis Among Patients with Poor Glycated Hemoglobic A1c (HbA1c) Control

9:00AM-11:00AM: Abstract Number: 1475

Eicosanoid Mediators of Systemic Inflammation and Arthritis in the Elderly

9:00AM-11:00AM: Abstract Number: 1499

Elevated Serum MMP-3 in Remission Predicts Relapsed in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1478

Factors Associated with Disability and Health-Related Quality of Life in Biologic-Treated Patients with Rheumatoid Arthritis in Persistent Moderate Disease Activity

9:00AM-11:00AM: Abstract Number: 1462

Fibrin Deposition and Neutrophil Infiltration of Rheumatoid Arthritis Synovium Are Associated with Duration of Morning Stiffness

9:00AM-11:00AM: Abstract Number: 1488

Identification of Joint Locations That Are Poor Prognostic in an Early Seropositive Erosive RA Cohort

9:00AM-11:00AM: Abstract Number: 1458

Impact of the Joint Presence of Erosions and ACPA on Rheumatoid Arthritis Disease Activity over Time: Results from the Meteor Registry

9:00AM-11:00AM: Abstract Number: 1476

Implication of CXCL5 (Epithelial neutrophil-activating peptide 78) in the Development of Insulin Resistance in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1486

Incidence of Subclinical Signs of Inflammation in Patients with New Onset of Non-Specific Musculoskeletal Symptoms and Anti-Citrullinated Peptide Positivity: First Interims Analysis of the Panora Trial

9:00AM-11:00AM: Abstract Number: 1482

Is 14.3.3η a Predictor of Development of Rheumatoid Arthritis in Patients with Early Undifferentiated Arthritis?

9:00AM-11:00AM: Abstract Number: 1454

Levels of 14-3-3eta Are an Independent Predictor of Long-Term Radiographic Erosive Progression and of Short-Term Rapid Radiographic Erosive Progression in Patients with Inflammatory Polyarthritis

9:00AM-11:00AM: Abstract Number: 1469

Measurement of Anti-Amyloid β Autoantibodies in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1492

Methotrexate Response in Early Rheumatoid Arthritis Predicted Using a Somamer Proteomic Assay

9:00AM-11:00AM: Abstract Number: 1449

Microwave Radiometry As a Novel Additional Method for Rheumatoid Arthritis Disease Activity Assessment: A Prospective Single-Center Study

9:00AM-11:00AM: Abstract Number: 1468

Minor Salivary Gland Biopsy: Its Importance in Rheumatoid Arthritis and Secondary Sjögren’s Syndrom

9:00AM-11:00AM: Abstract Number: 1445

MRI Bone Erosions in RA Patients Relatives with Clinically Suspicious Arthralgia

9:00AM-11:00AM: Abstract Number: 1456

Neutrophil Activation Is Associated with Disease Activity and Predicts Development of Erosive Disease and Extra Articular Manifestations in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1464

Newer Generation Cyclic Citrullinated Peptide (CCP) 3.1 Assay in the Diagnosis of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1491

Oestrogen Levels and the Outcome of Leflunomide Treatment in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1444

Optimization of Ultrasonographic Examination for the Diagnosis of Erosive Rheumatoid Arthritis Versus Erosive Osteoarthritis with Radiography Considered As Gold Standard

9:00AM-11:00AM: Abstract Number: 1461

Peptidylarginine Deiminase-4 Antibodies Are Not Associated with Worse RA Activity, Symptoms or Impacts

9:00AM-11:00AM: Abstract Number: 1473

Performance of the Meso Scale Multiplex Platform in the Assessment of Serum Cytokines / Chemokines in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1460

Plasma Mir-146a-5p Associates with Beneficial Body Composition and Plasma Metabolic Profiles in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1502

Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors

9:00AM-11:00AM: Abstract Number: 1507

Predictors of Fatigue and Persistent Fatigue in Early Rheumatoid Arthritis: A Longitudinal Observational Study

9:00AM-11:00AM: Abstract Number: 1494

Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches

9:00AM-11:00AM: Abstract Number: 1472

Preliminary Analysis of Genetic Variants in the Immune System Related to the Body Mass Index in Early Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1497

PRISM-RA: A Personalized Medicine Test That Accurately Predicts Rheumatoid Arthritis Patients Who Will Not Respond Adequately to Tumor Necrosis Factor Inhibitors

9:00AM-11:00AM: Abstract Number: 1480

Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database

9:00AM-11:00AM: Abstract Number: 1467

Rheumatoid Arthritis Activity Monitoring and Multiplex Biomarker Verification By Tageted Proteomics

9:00AM-11:00AM: Abstract Number: 1503

Rheumatoid Factor Positivity Is Related with Higher Discontinuation Rate of Tumor Necrosis Factor Inhibitor Therapy Due to Adverse Event and Insufficient Response in Rheumatoid Arthritis: A Multiple Imputation Method for COX Proportional Hazard Model

9:00AM-11:00AM: Abstract Number: 1470

Russell Bodies and Serological Status in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1477

Serum Autoantibody Multi-Analyte Testing in Rheumatoid Arthritis Can Reduce Avoidable Costs Associated from False Positive Results. a Simulation Study in the United States of America

9:00AM-11:00AM: Abstract Number: 1498

Serum MMP-3 More Than 155ng/Ml at Baseline Predicts One-Year Radiographic Progression in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1496

Sex Differences in the Achievement of Clinical Remission and Low MRI Synovitis Scores in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 1485

Survivin Measurements Improve Prediction of Rheumatoid Arthritis Among Patients with Unexplained Arthralgia

9:00AM-11:00AM: Abstract Number: 1506

Synovial Tissue Histopathology Findings in EARLY RA. Is It Usefull? Analysis of the Belgian CAP48 Cohort

9:00AM-11:00AM: Abstract Number: 1500

The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 1446

The Optimal Joint Set for Ultrasound Assessment of Synovitis in RA: Results from the Rasch Measurement Model

9:00AM-11:00AM: Abstract Number: 1505

The Point-of-Care Ichroma Anti-CCP Test Showed a Competitive Measurement Accuracy, in Comparison to the Conventional Automated Tests

9:00AM-11:00AM: Abstract Number: 1479

The Predictive Utility of Anti-Cyclic Citrullinated Peptide Antibodies to Diagnose Rheumatoid Arthritis in Patients with Hepatitis C and Polyarthralgias

9:00AM-11:00AM: Abstract Number: 1451

The Value of Adding MRI to a Clinical Treat-to-Target Strategy in Rheumatoid Arthritis Patients in Clinical Remission: Clinical and Radiographic Outcomes from the Imagine-RA Randomized Controlled Trial

9:00AM-11:00AM: Abstract Number: 1443

Ultrasonographic Criteria for the Diagnosis of Erosive Rheumatoid Arthritis Disease Using Osteoarthritic Patients As Controls Compared to Validated Radiographic Criteria

9:00AM-11:00AM: Abstract Number: 1504

Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1484

Value of Anti-RA33 Isotypes in an European Rheumatoid Arthritis Patient Cohort

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].